INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Institut
Istituto Oncologico della Svizzera Italiana
Bellinzona, SuizaPublikationen in Zusammenarbeit mit Forschern von Istituto Oncologico della Svizzera Italiana (11)
2024
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry
Hematological Oncology, Vol. 42, Núm. 1
2023
-
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655
-
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
eClinicalMedicine, Vol. 58
2022
-
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia
Leukemia and Lymphoma, Vol. 63, Núm. 5, pp. 1058-1069
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
Nature Medicine, Vol. 28, Núm. 8, pp. 1662-1671
-
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Blood, Vol. 140, Núm. 21, pp. 2248-2260
-
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384
2018
-
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet Haematology, Vol. 5, Núm. 11, pp. e563-e598
2015
-
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma
Leukemia, Vol. 29, Núm. 2, pp. 464-473